Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic Rituximab for Reducing EBV Viremia After Allo-HSCT
NCT07703657Not yet recruiting
- Start
- Jul 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Randomised, open-label trial of rituximab in Epstein-Barr virus infection (2 arms). Primary endpoint: Cumulative incidence of clinically significant EBV DNAemia at 180 days. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
rituximab
03
Conditions
Epstein-Barr virus infection
Beyond the preview
Go deeper on NCT07703657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07703657.